Citations

Clear

4847 citation(s) found for "Yu, Eric".

Rapid Early Progression (REP) of Glioblastoma Is an Independent Negative Prognostic Factor: Results From a Systematic Review and Meta-Analysis
Hamer, Philip Witt De, Quiñones‐Hinojosa, Alfredo , Waqar, Mueez , Roncaroli, Federico , Lehrer, Eric J. , Palmer, Joshua D. , Villanueva-Meyer, Javier E. , Braunstein, Steve , Hall, Emma , Aznar, Marianne Camille , D’Urso, Pietro Ivo , Trifiletti, Daniel M. , Wesseling, Pieter , Borst, Gerben R.

Mayo Clinic

Neuro-Oncology | October 1, 2022 | Volume: 24 | Issue: Supplement_4 | Pages: iv14-iv14

10.1093/neuonc/noac200.062 Get It

Abstract AIMS In patients with newly-diagnosed glioblastoma, rapid early progression (REP) refers to tumour regrowth between surgery and postoperative chemoradiotherapy. This systematic review and meta-analysis aimed to appraise published data on REP to better characterise and understand this phenomenon. METHOD Systematic searches of MEDLINE, EMBASE and the Cochrane database from inception to 21/10/21. Studies describing the incidence of REP – tumour growth between the postoperative MRI scan and pre-radiotherapy MRI scan in newly-diagnosed glioblastoma, were included. The primary outcome was REP incidence. RESULTS From 1590 search results, 9 studies were included with 716 patients. The median age was 56.9 years (IQR 54.0- 58.8 years). There was a male predominance with a median male-to-female ratio of 1.4 (IQR 1.1-1.5). The median number of days between MRI scans was 34 days (IQR 18-45 days). The mean incidence rate of REP was 45.9% (range 19.3%-72.0%) and significantly lower in studies employing functional imaging to define REP (p<0.001). REP/non-REP groups were comparable with respect to age (p=0.99), gender (p=0.33) and time between scans (p=0.81). REP was associated with shortened overall survival (HR 1.78, 95% CI 1.30-2.43, p<0.001), shortened progression-free survival (HR 1.78, 95% CI 1.30-2.43, p<0.001), subtotal resection (OR 6.96, 95% CI 4-51-10.73, p<0.001) and IDH wildtype versus mutant tumours (OR 0.20, 95% CI 0.02-0.38, p=0.03). MGMT promoter methylation was not associated with REP (OR 1.29, 95% CI 0.72-2.28, p=0.39). CONCLUSION REP occurs in almost half of patients with newly-diagnosed glioblastoma and has a strongly negative prognostic effect. Future studies should investigate its biology and effective treatment strategies.
Outcomes of Malignancy in Adults with Congenital Heart Disease: A Single Center Experience
Venkatesh, Prashanth , Yan, Kimberly , Lluri, Gentian , Bravo‐Jaimes, Katia , Yang, Eric H.

Mayo Clinic

No container title available | September 30, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2109843/v1 Get It

Abstract Background Malignancy is known to be a major cause of death in adult congenital heart disease (ACHD). However, data regarding cardiovascular and cancer-related outcomes in ACHD are lacking. Methods We conducted a retrospective single-center cohort study comprising patients with ACHD and malignancy. The primary outcome was all-cause mortality. Key Secondary outcomes included major adverse cardiovascular and cerebrovascular events (MACCE), cardiotoxicity events and consequent cancer therapy modifications. Results Sixty-eight patients with ACHD and a history of cancer were included in the study. 82% of patients had moderate or great ACHD anatomic complexity. Over a median follow-up of 5 years after cancer diagnosis, 16 (24%) patients died, with 69% of deaths being due to cancer. Univariate predictors of mortality were baseline arrhythmia (OR 3.82, 95% CI 1.15-12.67, p = 0.028), baseline diuretic therapy (OR 3.54, 95% CI 1.04-12.04, p = 0.044) and advanced cancer stage at diagnosis (OR 2.37, 95% CI 1.32-4.25, p = 0.004). MACCE occurred in 40 (59%) patients and was independently predicted by baseline diuretic requirement (OR 9.91, 95% CI 1.12 - 87.85, p = 0.039). A14% incidence of cardiotoxicity was seen; 3 patients needed modification and 1 patient needed temporary interruption of cancer therapy for 2 weeks. Conclusions Considerable mortality occurred in this cohort of patients with ACHD and cancer; most deaths were cancer-related. A high rate of MACCE was observed, yet rates of obligatory modification of cancer therapy due to cardiotoxicity were low.
Dynamic CT Angiography in Vascular Imaging: Principles and Applications
Rajiah, Prabhakar , Weber, Nikkole M. , Loewen, Jennifer M. , Kasten, Holly J., Williamson, Eric , Moore, Alastair , Leng, Shuai , Rajiah, Prabhakar , Weber, Nikkole , Loewen, Jennifer , Kasten, Holly, Leng, Shuai

Mayo Clinic

RadioGraphics | September 30, 2022 | Volume: 42 | Issue: 7 | Pages: E224-E225

10.1148/rg.210177 | PMID 36178805 Get It

Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease
Roofeh, David , Brown, Kevin M. , Kazerooni, Ella A. , Tashkin, Donald P. , Assassi, Shervin , Martínez, Fernando J. , Wells, Athol U. , Raghu, Ganesh , Denton, Christopher P. , Chung, Leland W.K. , Matteson, Eric L. , Pauling, John D , Seibold, James R. , Volkmann, Elizabeth R. , Walsh, Simon , White, Eric S. , Barratt, Shaney , Domsic, Robyn T. , Dellaripa, Paul F. , Rosas, Iván O. , Bhatt, Nitin, Hsu, Vivien , Kahaleh, Bashar , Garcha, Puneet , Khanna, Surabhi , Lin, Celia J. F., Mathai, Stephen C. , Doyle, Tracy J. , Steen, Virginia , Zoz, Donald F., Rodríguez‐Pintó, Ignasi , Lewandoski, Andrew, Belloli, Elizabeth A. , Lescoat, Alain , Nagaraja, Vivek , Ye, Wen , Huang, Suiyuan, Maher, Toby M. , Khanna, Dinesh , Tashkin, Donald , Martinez, Fernando , Chung, Lorinda , Hoffmann-Vold, Anna-Maria , Distler, Oliver , Johannson, Kerri A , Allanore, Yannick , Matteson, Eric L , Kawano-Dourado, Leticia , Pauling, John D , Seibold, James R , Volkmann, Elizabeth R , Oddis, Chester V , White, Eric S , Barratt, Shaney L , Bernstein, Elana J , Domsic, Robyn T , Dellaripa, Paul F , Conway, Richard , Rosas, Ivan , Hsu, Vivien , Ingegnoli, Francesca , Kahaleh, Bashar , Garcha, Puneet , Gupta, Nishant , Korsten, Peter , Strand, Vibeke , Steen, Virginia , Ovalles-Bonilla, Juan , Rodriguez-Pinto, Ignasi , Shenoy, Padmanabha D , Lescoat, Alain , Nagaraja, Vivek , Maher, Toby , Khanna, Dinesh , Assassi, Shervin , Mathai, Stephen C , Hoffmann‐Vold, Anna‐Maria , Distler, Oliver , Kawano-Dourado, Letícia , Oddis, Chester V. , Bernstein, Elana J. , Conway, Richard , Ingegnoli, Francesca , Gupta, Nishant , Korsten, Peter , Lewandoski, Andrew

Mayo Clinic

Rheumatology | September 29, 2022 | Volume: 62 | Issue: 5 | Pages: 1877-1886

10.1093/rheumatology/keac557 | PMID 36173318 Get It

Abstract Objectives To establish a framework by which experts define disease subsets in systemic sclerosis associated interstitial lung disease (SSc-ILD). Methods A conceptual framework for subclinical, clinical and progressive ILD was provided to 83 experts, asking them to use the framework and classify actual SSc-ILD patients. Each patient profile was designed to be classified by at least four experts in terms of severity and risk of progression at baseline; progression was based on 1-year follow-up data. A consensus was reached if ≥75% of experts agreed. Experts provided information on which items were important in determining classification. Results Forty-four experts (53%) completed the survey. Consensus was achieved on the dimensions of severity (75%, 60 of 80 profiles), risk of progression (71%, 57 of 80 profiles) and progressive ILD (60%, 24 of 40 profiles). For profiles achieving consensus, most were classified as clinical ILD (92%), low risk (54%) and stable (71%). Severity and disease progression overlapped in terms of framework items that were most influential in classifying patients (forced vital capacity, extent of lung involvement on high resolution chest CT [HRCT]); risk of progression was influenced primarily by disease duration. Conclusions Using our proposed conceptual framework, international experts were able to achieve a consensus on classifying SSc-ILD patients along the dimensions of disease severity, risk of progression and progression over time. Experts rely on similar items when classifying disease severity and progression: a combination of spirometry and gas exchange and quantitative HRCT.
Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer
Aggarwal, Rahul , Alumkal, Joshi J. , Higano, Celestia S. , Bryce, Alan H. , Lopez‐Gitlitz, Angela , McCarthy, Sharon , Miladinović, Branko, McQuarrie, Kelly , Thomas, Shibu , Zhang, Ke , Bryce, Alan H , Szmulewitz, Russell Z , Small, Eric J.

Mayo Clinic

Prostate Cancer | September 29, 2022 | Volume: 2022 | Issue: No issue available | Pages: 1-12

10.1155/2022/5454727 | PMID 36212187 Get It

Purpose. This randomized phase 2 study sought to assess the treatment effect of a finite duration of apalutamide with and without androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BCR PC). Materials and Methods. Patients with BCR PC after primary definitive therapy and prostate-specific antigen (PSA) doubling time ≤12 months were randomized to open-label apalutamide (240 mg/d) alone, apalutamide plus ADT, or ADT alone (1 : 1:1 ratio) for 12 months followed by a 12-month observation period (NCT01790126). Mean changes from baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) at 12 months (primary endpoint) and other prespecified assessments of health-related quality of life (HRQoL), PSA nadir, time to PSA progression, time to testosterone recovery, recovered testosterone >150 ng/dL without PSA progression at 24 months, and molecular markers were evaluated. Results. In 90 enrolled patients (apalutamide plus ADT (n = 31), apalutamide (n = 29), ADT (n = 30)), FACT-P at 12 months was not significantly different between apalutamide, ADT and apalutamide, and ADT groups. Addition of apalutamide to ADT prolonged time to PSA progression but this change did not reach statistical significance (hazard ratio (HR): 0.56, 95% confidence interval (CI): 0.23–1.36, P = 0.196 ); time to testosterone recovery was similar in the ADT-containing groups. In apalutamide plus ADT, apalutamide, and ADT groups, 37.9%, 37.0%, and 19.2% of patients, respectively, had testosterone >150 ng/dL at 24 months without confirmed PSA progression. Of the few biomarkers expressed in blood, EPHA3 was significantly associated with shorter time to PSA progression ( P = 0.02 ) in the overall population. Conclusions. HRQoL was similar in patients treated with apalutamide alone, ADT alone, or their combination, although apalutamide plus ADT did not demonstrate statistically significant noninferiority in change from baseline in overall HRQoL. The aggregated efficacy and safety outcomes support further evaluation of apalutamide plus ADT in BCR PC.
Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosis
Desai, Sanjal H. , Mwangi, Raphael , Ng, Wern Lynn , King, Rebecca L. , Maurer, Matthew J. , Cerhan, James R. , Feldman, Andrew L. , Farooq, Umar , Mou, Eric , Thompson, Carrie A. , Nowakowski, Grzegorz S. , Wang, Yucai , Witzig, T.E. , Feldman, Andrew L , Maurer, Matthew , Cerhan, James R , Farooq, Umar , Desai, Sanjal , Mou, Eric , Habermann, Thomas M. , Wang, Yucai , Witzig, Thomas E.

Mayo Clinic

Blood Advances | September 28, 2022 | Volume: 6 | Issue: 24 | Pages: 6180-6186

10.1182/bloodadvances.2022007569 | PMID 36170803 Get It

Abstract An enhanced understanding of the molecular heterogeneity of diffuse large B-cell lymphoma (DLBCL) has opened the door to clinical trials evaluating novel agents with subtype-specific activity. It is an emerging question whether core needle biopsies (CNB) can adequately meet the increasing tissue requirements of these clinical trials. This can potentially lead to selective enrollment of patients who can undergo excisional biopsy (EB). It is also important to know whether patients who can undergo extensive diagnostic work up differ in their disease characteristics and outcomes from those who cannot. In this observational study, we describe the characteristics, outcomes, and adequacy of diagnostic tissue in patients with newly diagnosed DLBCL and primary mediastinal large B-cell lymphoma who underwent EB vs CNB. Of the 1061 patients, 532 (49.8%) underwent EB and 529 (50.1%) underwent CNB. A significantly higher proportion of patients with CNB had advanced stage disease, an international prognostic index of ≥3, and inadequate tissue for molecular analyses. Patients with CNB had significantly worse 5-year event-free survival (67.6% vs 56.9%; hazard ratio [HR], 0.76; confidence interval [CI]95, 0.6-0.9, P < .001) and 5-year overall survival (76.4% vs 69.2%; HR, 0.8; CI95, 0.6-0.9, P < .001). Thus, patients who underwent CNB have poor-risk features and inferior outcomes on frontline chemoimmunotherapy, are more likely to have inadequate tissue for molecular analyses, and might not meet the tissue requirements of biomarker-driven clinical trials. Thus, the increasing tissue requirements of biomarker-driven clinical trials may result in the exclusion of patients with high-risk DLBCL who need novel agents.
Amyloid‐Related Imaging Abnormalities in the DIAN‐TU‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease
Joseph‐Mathurin, Nelly , Li, Yan , McCullough, Austin , Hofmann, Carsten, Wojtowicz, Jakub , Park, Ethan, Wang, Guoqiao , Preboske, Gregory M., Gordon, Brian A. , Chen, Charles D., Flores, Shaney , Aggarwal, Neelum T. , Berman, Sarah , Bird, Thomas D., Borowski, Bret, Chhatwal, Jasmeer P. , Clarnette, Roger, Fagan, Anne M. , Farlow, Martin R. , Fox, Nick C. , Gauthier, Serge , Hassenstab, Jason , Hobbs, Diana A. , Holdridge, Karen C. , Hornbeck, Russ C. , Jiménez‐Velázquez, Ivonne Z. , Klein, Gregory , Xiong, Chengjie , Mancini, Michele , McKay, Nicole S. , Mummery, Catherine J. , Ringman, John M. , Snider, B. Joy, Suzuki, Kazushi , Yaari, R. , Perrin, Richard J. , Bateman, Randall J. , Salloway, Stephen , Clifford, David B., Unit, For the Dominantly Inherited Alzheimer Network Trials, Wang, Qing , Gordon, Brian A , Chen, Charles D , Jucker, Mathias , Ringman, John M , Salloway, Steve , Benzinger, Tammie L S , Bateman, Randall J , Joseph-Mathurin, Nelly , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Berman, Sarah , Llibre‐Guerra, Jorge J. , Li, Yan, Wáng, Qīng , Black, Sandra E. , Brooks, William S. , Cruchaga, Carlos , Honig, Lawrence S. , Hsiung, Ging‐Yuek Robin , Jack, Clifford R. , Masellis, Mario , Shimada, Hiroyuki , Wallon, David , Xiong, Chengjie , McDade, Eric , Benzinger, Tammie L.S. , Unit, For the Dominantly Inherited Alzheimer Network Trials

Mayo Clinic

Annals of Neurology | September 24, 2022 | Volume: 92 | Issue: 5 | Pages: 729-744

10.1002/ana.26511 | PMID 36151869 Get It

ObjectiveTo determine the characteristics of participants with amyloid‐related imaging abnormalities (ARIA) in a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease (DIAD).Methods142 DIAD mutation carriers received either gantenerumab SC (n = 52), solanezumab IV (n = 50), or placebo (n = 40). Participants underwent assessments with the Clinical Dementia Rating® (CDR®), neuropsychological testing, CSF biomarkers, β‐amyloid positron emission tomography (PET), and magnetic resonance imaging (MRI) to monitor ARIA. Cross‐sectional and longitudinal analyses evaluated potential ARIA‐related risk factors.ResultsEleven participants developed ARIA‐E, including 3 with mild symptoms. No ARIA‐E was reported under solanezumab while gantenerumab was associated with ARIA‐E compared to placebo (odds ratio [OR] = 9.1, confidence interval [CI][1.2, 412.3]; p = 0.021). Under gantenerumab, APOE‐ɛ4 carriers were more likely to develop ARIA‐E (OR = 5.0, CI[1.0, 30.4]; p = 0.055), as were individuals with microhemorrhage at baseline (OR = 13.7, CI[1.2, 163.2]; p = 0.039). No ARIA‐E was observed at the initial 225 mg/month gantenerumab dose, and most cases were observed at doses >675 mg. At first ARIA‐E occurrence, all ARIA‐E participants were amyloid‐PET+, 60% were CDR >0, 60% were past their estimated year to symptom onset, and 60% had also incident ARIA‐H. Most ARIA‐E radiologically resolved after dose adjustment and developing ARIA‐E did not significantly increase odds of trial discontinuation. ARIA‐E was more frequently observed in the occipital lobe (90%). ARIA‐E severity was associated with age at time of ARIA‐E.InterpretationIn DIAD, solanezumab was not associated with ARIA. Gantenerumab dose over 225 mg increased ARIA‐E risk, with additional risk for individuals APOE‐ɛ4(+) or with microhemorrhage. ARIA‐E was reversible on MRI in most cases, generally asymptomatic, without additional risk for trial discontinuation. ANN NEUROL 2022;92:729–744
Correlation of the Modified Japanese Orthopedic Association With Functional and Quality-of-Life Outcomes After Surgery for Degenerative Cervical Myelopathy: A Quality Outcomes Database Study
Yee, Timothy J., Upadhyaya, Cheerag D., Coric, Domagoj , Potts, Eric A. , Bisson, Erica F. , Turner, Jay D. , Knightly, Jack, Fu, Kai-Ming, Foley, Kevin T. , Tumialán, Luis M. , Shaffrey, Mark E., Bydon, Mohamad , Mummaneni, Praveen V. , Chou, Dean , Chan, Andrew K. , Meyer, Scott A., Asher, Anthony L. , Shaffrey, Christopher I. , Gottfried, Oren N., Than, Khoi D. , Wang, Michael Y. , Buchholz, Avery L., Haid, Regis W., Park, Paul

Mayo Clinic

Neurosurgery | September 23, 2022 | Volume: 91 | Issue: 6 | Pages: 952-960

10.1227/neu.0000000000002161 | PMID 36149088 Get It

BACKGROUND: The modified Japanese Orthopedic Association (mJOA) score is a widely used and validated metric for assessing severity of myelopathy. Its relationship to functional and quality-of-life outcomes after surgery has not been fully described. OBJECTIVE: To quantify the association of the mJOA with the Neck Disability Index (NDI) and EuroQol-5 Dimension (EQ-5D) after surgery for degenerative cervical myelopathy. METHODS: The cervical module of the prospectively enrolled Quality Outcomes Database was queried retrospectively for adult patients who underwent single-stage degenerative cervical myelopathy surgery. The mJOA score, NDI, and EQ-5D were assessed preoperatively and 3 and 12 months postoperatively. Improvement in mJOA was used as the independent variable in univariate and multivariable linear and logistic regression models. RESULTS: Across 14 centers, 1121 patients were identified, mean age 60.6 ± 11.8 years, and 52.5% male. Anterior-only operations were performed in 772 patients (68.9%). By univariate linear regression, improvements in mJOA were associated with improvements in NDI and EQ-5D at 3 and 12 months postoperatively (all P < .0001) and with improvements in the 10 NDI items individually. These findings were similar in multivariable regression incorporating potential confounders. The Pearson correlation coefficients for changes in mJOA with changes in NDI were −0.31 and −0.38 at 3 and 12 months postoperatively. The Pearson correlation coefficients for changes in mJOA with changes in EQ-5D were 0.29 and 0.34 at 3 and 12 months. CONCLUSION: Improvements in mJOA correlated weakly with improvements in NDI and EQ-5D, suggesting that changes in mJOA may not be a suitable proxy for functional and quality-of-life outcomes.
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
Duncavage, Eric J., Bagg, Adam , Hasserjian, Robert P. , DiNardo, Courtney D. , Iacobucci, Ilaria , Jaiswal, Siddhartha , Vannucchi, Alessandro M. , Patel, Keyur P. , Arcila, Maria E. , Borowitz, Michael J., Cargo, Catherine , Garcia‐Manero, Guillermo , Haferlach, Torsten , Hellström‐Lindberg, Eva , Klco, Jeffery M. , Loh, Mignon Lee-Cheun, Papaemmanuil, Elli , Reiter, Andreas , Skoda, Radek C. , Solé, Françesc , Stone, Richard M. , Tefferi, Ayalew , Wu, David , Ebert, Benjamin L. , Cazzola, Mario , Godley, Lucy A , Iacobucci, Ilaria , Jaiswal, Siddhartha , Malcovati, Luca , Vannucchi, Alessandro M , Patel, Keyur P , Arber, Daniel A , Bejar, Rafael , Branford, Susan , Brown, Anna L , Döhner, Hartmut , Falini, Brunangelo , Kim, Annette S , Komrokji, Rami S , Loghavi, Sanam , Mullighan, Charles G , Ogawa, Seishi , Ross, David M , Savona, Michael R , Shimamura, Akiko , Solé, Francesc , Walter, Matthew J , Wu, David , Ebert, Benjamin L , Cazzola, Mario , DiNardo, Courtney , Godley, Lucy A. , Malcovati, Luca , Arber, Daniel A. , Berliner, Nancy , Branford, Susan , Brown, Anna , Falini, Brunangelo , Komrokji, Rami S. , Loh, Mignon L. , Loghavi, Sanam , Mullighan, Charles G. , Orazi, Attilio , Savona, Michael R.

Mayo Clinic

Blood | September 21, 2022 | Volume: 140 | Issue: 21 | Pages: 2228-2247

10.1182/blood.2022015853 | PMID 36130297 Get It

Abstract Myeloid neoplasms and acute leukemias derive from the clonal expansion of hematopoietic cells driven by somatic gene mutations. Although assessment of morphology plays a crucial role in the diagnostic evaluation of patients with these malignancies, genomic characterization has become increasingly important for accurate diagnosis, risk assessment, and therapeutic decision making. Conventional cytogenetics, a comprehensive and unbiased method for assessing chromosomal abnormalities, has been the mainstay of genomic testing over the past several decades and remains relevant today. However, more recent advances in sequencing technology have increased our ability to detect somatic mutations through the use of targeted gene panels, whole-exome sequencing, whole-genome sequencing, and whole-transcriptome sequencing or RNA sequencing. In patients with myeloid neoplasms, whole-genome sequencing represents a potential replacement for both conventional cytogenetic and sequencing approaches, providing rapid and accurate comprehensive genomic profiling. DNA sequencing methods are used not only for detecting somatically acquired gene mutations but also for identifying germline gene mutations associated with inherited predisposition to hematologic neoplasms. The 2022 International Consensus Classification of myeloid neoplasms and acute leukemias makes extensive use of genomic data. The aim of this report is to help physicians and laboratorians implement genomic testing for diagnosis, risk stratification, and clinical decision making and illustrates the potential of genomic profiling for enabling personalized medicine in patients with hematologic neoplasms.